Home
Dianthus Therapeutics

Dianthus Therapeutics Market Share Analysis for August 2026

Dianthus Therapeutics is harnessing the power of selectivity to advance next-generation complement therapies.

Industry: N/A

Domaindianthustx.com

Year Founded2019

Employees51 - 200

Annual Revenue$2M - $5M

Dianthus Therapeutics

Dianthus Therapeutics (including company regionals)

dianthustx.com

See more website traffic and engagement information

Dianthus Therapeutics Revenue up to August 2026 is 2M - 5M

revenue generated by Dianthus Therapeutics top domains

Dianthus Therapeutics top domains revenue over 3 years

Revenue for Dianthus Therapeutics top domains

dianthustx.com2M - 5M

See more with Sales Intelligence

Total visits to Dianthus Therapeutics's top domains

Understand Dianthus Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

dianthustx.com20.9K

See more with Sales Intelligence

Avg. visit duration in Dianthus Therapeutics's top domains

Analyze Dianthus Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

dianthustx.com00:01:40

See more with Sales Intelligence

Avg. pageviews on Dianthus Therapeutics's top domains

See how Dianthus Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

dianthustx.com1.44

See more with Sales Intelligence

Dianthus Therapeutics top competitors by domain

Top similar sites in August 2026, ranked by their affinity

zenasbio.comCompany NameZenas BioPharmaEmployees51 - 200HQUnited States, Massachusetts, WalthamAnnual revenue$10M - $15MTotal visits11.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Dianthus Therapeutics

These are the website technologies, by industry, used by Dianthus Therapeutics top domains

Widget (3)

Twemoji

Advertising (2)

Google Adsense

Email Services (2)

Microsoft Exchange Online

Mobile (2)

Meta Viewport

More Technologies

7

See all

News & Signals from Dianthus Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDianthus Therapeutics Inc had revenue of $760K on Aug 4th '26.* Dianthus Therapeutics reported a quarterly loss of $0.90 per share, missing analyst expectations by $0.05, while revenue of $0.76 million exceeded the $0.30 million consensus estimate.

NewsDianthus Therapeutics Inc launched DNTH312 on Aug 4th '26.Dianthus Therapeutics announces DNTH312, a first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI, for severe autoimmune diseases.

NewsDianthustx is developing experimental therapy DNTH212.Dianthus to develop experimental therapy DNTH212 for Sjögren's.